Clinical Trial Finder | Pancreatic Cancer Action Network

Back to Trial Search

A Phase 1b/2a Study of Gemcitabine and Nab-paclitaxel in Combination With Avutometinib (VS-6766) and Defactinib in Patients With Previously Untreated Metastatic Adenocarcinoma of the Pancreas

Summary

The purpose of this phase I/II study is to evaluate the safety and efficacy of Avutometinib (VS-6766) and Defactinib in combination with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma.

General Information

NCT#: NCT05669482
Study ID: VS-6766-205
Trial Phase: Phase I/II

Trial Sponsor: Verastem, Inc.
Therapies Used in This Trial: Nab-paclitaxel, Gemcitabine, Defactinib, Avutometinib

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account? Sign In

Request an Account

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account.
In order to view this information, you need to be signed in as a Health Care Provider.
In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
This information is restricted to validated Health Care Providers.

Eligibility

-------------------------------------------------------------------------------------------

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
------------------------------------------------------------------------------------------------------
In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information

Back to Trial Search